Research chemical vendors sometimes list compounds under investigational names, but without regulatory oversight, independent third-party testing, and pharmaceutical-grade manufacturing standards, there is no way to verify what you are actually receiving
The first GLP- 1 medication (Exenatide) was approved in 2005 by the U.S
Context matters enormously
Patients should not discontinue semaglutide due to UTI concerns without consulting their prescribing physician, as the metabolic benefits typically outweigh any theoretical indirect risks
Because GLP-1 drugs are not opioid-based treatments and are not primarily SUD treatments, they are positioned to completely bypass the culture wars surrounding substance use treatment, which will enable them to have a dramatic impact on the global prevalence of addiction, at a scale that existing treatments cannot reach
Cao B, Jin M, Brietzke E, McIntyre RS, Wang D, Rosenblat JD, Ragguett RM, Zhang C, Sun X, Rong C, et al
.webp)
